13F Filings History of GILEAD SCIENCES, INC.

Latest 13F filing: Q1 2026 - 08 May 2026
Latest reported 13F value: $2,117,784,504
Largest 13F holdings: ACLX RCUS GLPG ASMB KYTX XLO
Form 13F summary: GILEAD SCIENCES, INC. Form 13F history summarizes parsed U.S.-listed equity disclosures for this manager.
Form 13F is generally due within 45 days after each calendar quarter ends.
GILEAD SCIENCES, INC. reported 6 equity holdings with a total reported market value of $2,117,784,504 for Q1 2026. Top reported holdings included ACLX, RCUS, GLPG, ASMB, and KYTX.
Manager signature: Andrew D. Dickinson - Executive Vice President and Chief Financial Officer
Manager location: Foster City, CA

Follow Filing Activity

Follow GILEAD SCIENCES, INC. with Pro and return when a new 13F portfolio filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Holdings Value

Form 13F evidence

Quarterly portfolio filings

SEC-reported 13F quarters for this filer, ordered by the latest accepted filing.

Latest quarter

Q1 2026

Latest value

$2,117,784,504

Quarter delta

+$182,276,650

Accepted

08 May 2026, 17:00

Rows shown

1-6 of 6

Quarter	Holdings	SEC-reported value	Bought	Sold	Net	Top Holdings	Form Type	Accepted by SEC
Q1 2026	6	$2,117,784,504	$0	-$71,107,065	-$71,107,065	ACLX, RCUS, GLPG, ASMB, KYTX	13F-HR	08 May 2026, 17:00
Q4 2025	6	$1,935,507,854	$0	-$85,797,631	-$85,797,631	RCUS, GLPG, ACLX, ASMB, KYTX	13F-HR	12 Feb 2026, 16:36
Q3 2025	9	$1,791,467,184	+$58,775,552	-$5,069,444	+$53,706,108	GLPG, ACLX, RCUS, ASMB, MRUS	13F-HR	13 Nov 2025, 16:44
Q2 2025	14	$1,280,204,668	$0	-$2,420,378	-$2,420,378	GLPG, ACLX, RCUS, ASMB, TNGX	13F-HR	14 Aug 2025, 10:58
Q1 2025	14	$1,181,331,731	+$16,512,425	-$9,131,340	+$7,381,085	ACLX, GLPG, RCUS, ASMB, MRUS	13F-HR	13 May 2025, 16:15
Q4 2024	16	$1,551,148,266	$0	$0	$0	ACLX, GLPG, RCUS, ASMB, MRUS	13F-HR	13 Feb 2025, 16:14